Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 6—June 2011

Dispatch

Macrolide Resistance in Mycoplasma pneumoniae, Israel, 2010

Diana Averbuch, Carlos Hidalgo-Grass, Allon E. Moses, Dan Engelhard, and Ran Nir-PazComments to Author 
Author affiliations: Author affiliation: Hadassah–Hebrew University Medical Center, Jerusalem, Israel

Main Article

Table

Clinical information of patients positive for Mycoplasma pneumoniae, according to macrolide resistance genotype, Israel, 2010

Characteristic Macrolide-sensitive M. pneumoniae, n = 19* Macrolide-resistant M. pneumoniae, n = 9
Mean age, y, ± SD 7 ± 14.98 9 ± 8.39
>21
3
1
Admission, mean d, ± SD 4 ± 6.6 3 ± 8.2
Pneumonia confirmed by chest radiograph
16
9
Male/female 6/13 4/5
Ethnicity (Arab/Jewish)
5/14
1/8
Complications† 3 0
Concurrent conditions‡
4
2
Prior antibiotic use 9 6
Prior macrolide use 3 2

*Values are no. patients except as indicated. Clinical data were not available for 2 patients.
†Two patients had Stevens-Johnson syndrome, and Still’s disease developed in 1 patient.
‡Four patients had asthma, 1 had metabolic syndrome with cardiomyopathy, and 1 had carcinoma of the pancreas.

Main Article

1These authors contributed equally to this article.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO